Macfarlanes advises Exponent Private Equity on significant investment into Xeinadin Group
Created via the combination of over 100 small and medium-sized businesses, Xeinadin is a large consolidator in the professional services market, with more than 100 locations across the UK and Ireland, providing over 40 service lines to around 50,000 clients.
Exponent's investment will support Xeinadin’s strategy for growth both organically and through acquisitions, allowing it to make further investments in innovative data-driven technologies to enhance service delivery to its clients.
Subject to regulatory approvals, the transaction is expected to complete in Q1 2022.
This mandate continues Macfarlanes’ long-standing relationship with Exponent which has seen the firm advise on a number of acquisitions and disposals over the years.
The Macfarlanes team for this matter was led by corporate and M&A partner Stephen Drewitt with assistance from senior consultant William David, senior solicitor Alice Temkin and solicitors Ian Davis, Jaani Patheja and Bryony Foley. Investment management advice was provided by senior counsel Chris Daniel, tax expertise came from senior counsel Sarah Shucksmith and senior solicitor Andrew Morrison provided assistance on competition law. Partner Hayley Robinson and senior solicitor Chris Boyle advised on the employment elements of the deal.
